Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tonogenchoncel-L - Kolon TissueGene

Drug Profile

Tonogenchoncel-L - Kolon TissueGene

Alternative Names: Invossa; Invossa K Inj.; Invossa K Injection; INVOSSA-K inj; TG C; TGF-beta-1 gene therapy - Kolon TissueGene; TissueGene-C; TissueGene-C(S); Transforming growth factor-beta-1 gene therapy - Kolon TissueGene

Latest Information Update: 28 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TissueGene
  • Developer Kolon Life Science; Kolon TissueGene
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Chondrocytes replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Osteoarthritis
  • Preclinical Intervertebral disc degeneration; Rheumatoid arthritis

Most Recent Events

  • 19 Dec 2023 Kolon TissueGene plans a phase I trial for Intervertebral disc degeneration (Treatment-experienced) (Intra-articular, Injection) in USA in November 2025 (NCT06144970)
  • 18 Dec 2023 US FDA approves IND application for Tonogenchoncel-L in Intervertebral disc degeneration
  • 06 Nov 2023 Kolon TissueGene has patent protection for 'cartilage regeneration using cartilage cells and TGF-β' in China
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top